Beyond Neuprex!! Interesting use for LBP.
[USPTO]
( 15 of 15 )
United States Patent
5,230,886
Treon, et. al.
Jul. 27, 1993
Tumor cell suppression
Inventors:
Treon; Steven P. (W. Roxbury, MA); Broitman; Selwyn A. (Newton Highlands, MA).
Assignee:
Trustees of Boston University (Boston, MA).
Appl. No.:
853,132
Filed:
Mar. 18, 1992
Intl. Cl. :
A61K 45/00, A61K 37/66, A61K 37/02, A61K 37/04
Current U.S. Cl.:
424/85.1; 424/282.1; 424/85.4; 424/85.5; 424/85.6;
424/85.7; 514/21
Field of Search:
514/21; 424/85.1, 85.4, 85.5, 85.6, 85.7, 88
References Cited | [Referenced By]
U.S. Patent Documents
4,851,219
Jul., 1989
Sherwin
4,863,727
Sept., 1989
Zimmerman et al.
Other References
Spriggs, et al., "Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion.
A Phase I and Pharmacologic Study", Sep. 7, 1988, J. Natl. Cancer Inst., vol. 80, pp. 1039-1044.
Creaven P., et al., "A Phase I Clinical Trial of Recombinant Human Tumor Necrosis Factor Given Daily for
Five Days", 1989, Cancer Chemother. Pharmacol., vol. 23, pp. 186-191.
Lenk H., et al., "Phase II Clinical Trial of High-Dose Recombinant Human Tumor Necrosis Factor", 1989,
Cancer Chemother. Pharmacol., vol. 24, pp. 391-392.
Demetri, G., et al., "A Phase I Trial of Recombinant Human Tumor Necrosis Factor and Interferon-Gamma:
Effects of Combination Cytokine Administration In Vivo", Oct. 1989, Jour. Clin. Oncol., vol. 7, pp.
1545-1553.
Engelhardt, R., et al., "A Phase I Trial of Intravenously Administered Endotoxin", Mar. 1991, Proc. Am.
Assoc. Cancer Res., vol. 32, p. 268, A1594.
Kunkel, S. L., et al., "Regulation of Macrophage Tumor Necrosis Factor Production by Prostaglandin E(2) ",
1986, Bioc. Biop. Res. Comm., vol. 137, pp. 404-410.
Karck, U., et al., "The Release of Tumor Necrosis Factor From Endotoxin-Stimulated Rat Kupffer Cells is
Regulated by Prostaglandin E(2) and Dexamethasone", 1988, Jour. Hepat., vol. 7, pp. 352-361.
Levin S., et al., "Interferon System in Acute Viral Hepatitis", 1982, Lancet, vol. 1, pp. 592-594.
Treon, S. P., et al., "Demonstration of Concurrent Endotoxaemia and TNF-Aemia in Acute Viral Hepatitis
Patients", 1991, Gastroenterology, vol. 100, p. A845.
Michie, H. R., et al., "Detection of Circulating Tumor Necrosis Factor After Endotoxin Administration", Jun. 9,
1988, New Eng. Jour. Med., vol. 318, pp. 1481-1486.
Pelner, L., et al., "Effects of Concurrent Infections and Their Toxins on the Course of Leukemia", 1958, Acta
Med. Scand., vol. 338 (Suppl) pp. 1-47.
Barton, J. C., "Beneficial Effects of Hepatitis in Patients with Acute Myelogenous Leukemia", 1979, Ann. Int.
Med. vol. 90, pp. 188-190.
Barton, J. C., et al., "Prognostic Significance of Hepatitis in Acute Myelogenous Leukemia", 1979, Clin. Res.,
vol. 27, p. 490A.
Foon, K. A., et al., "Posttransfusion Hepatitis in Acute Myelogenous Leukemia", Oct. 17, 1980, JAMA, vol.
244, pp. 1806-1807.
Rotoli, B., et al., "Long-Term Survival in Acute Myelogenous Leukemia Complicated by Chronic Active
Hepatitis", 1982, New Eng. Jour. Med., vol. 307, pp. 1712-1713.
Helson, L., et al., "Effect of Tumour Necrosis Factor on Cultured Human Melanoma Cells", Dec. 1975,
Nature, vol. 258, pp. 731-732.
Peetre, C., et al., "Effects of Recombinant Tumor Necrosis Factor on Proliferation and Differentiation of
Leukemic and Normal Hemopoietic Cells In Vitro", 1986, Jour. Clin. Invest., vol. 78, pp. 1694-1700.
Munker R., et al., "In Vitro Action of Tumor Necrosis Factor on Myeloid Leukemia Cells", Apr. 1987, Blood,
vol. 69, pp. 1102-1108.
Sugarman, B. J., et al., "Recombinant Human Tumor Necrosis Factor-.alpha.: Effects on Proliferation of
Normal and Transformed Cells In Vitro", Nov. 1985, Science, vol. 230, pp. 943-945.
Craig, R. W., et al., "Differentiation-Inducing and Cytotoxic Effects of Tumor Necrosis Factor and
Interferon-Gamma in Myeloblastic ML-1 Cells", 1989, Jour. Cel. Physiol. vol. 141, pp. 46-52.
Haranaka, K., et al., "Antitumor Activity of Murine Tumor Necrosis Factor (TNF) Against Transplanted Human
Tumors in Nude Mice", May 27, 1984, Int. Jour. Cancer, vol. 34, pp. 263-267.
Rothstein, J. L., et al., "Synergy Between Tumor Necrosis Factor and Bacterial Products Causes Hemorrhagic
Necrosis and Lethal Shock in Normal Mice", 1988, Proc. Natl. Acad. Sci., USA, vol. 85, pp. 607-611.
Mannel, D. N., et al., "Macrophages as a Source of Tumoricidal Activity (Tumor-Necrotizing Factor)", 1980,
Infect. Immun., vol. 30, pp. 523-530.
Aggarwal, B. B., et al., "Human Tumor Necrosis Factor", 1985, Jour. Biol. Chem., vol. 260, pp. 2345-2354.
Mohri, M., et al., "Effects of Lipopolysaccharide on Phospholipase A, Activity and Tumor Necrosis Factor
Expression in HL-60 Cells", 1990, Jour. Immunol., vol. 144, pp. 2678-2682.
Tobias, P. S., et al., "Identification of a Lipid A Binding Site in the Acute Phase Reactant
Lipopolysaccharide Binding Protein", 1989, Jour. Biol. Chem., vol. 264, pp. 10867-10871.
Wright, S. D., et al., "CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding
Protein", 1990, Science vol. 249, pp. 1431-1433.
Primary Examiner: Wityshyn; Michael G.
Assistant Examiner: Koh; Choon P.
Attorney, Agent or Firm: Choate, Hall & Stewart
Abstract
A method for treating a cancer includes administration of an endotoxin to a patient at least a portion of whose neoplastic
cells express the CD14 surface receptor. The endotoxin can be administered concurrently or sequentially with a binding
protein capable of binding the endotoxin and, for example, where the endotoxin is a lipopolysaccharide or a nontoxic
portion of a lipopolysaccharide, it may for example be administered concurrently with a lipopolysaccharide
binding protein. Also, the method including a step of first determining whether a portion of the patient's neoplastic
cells express the CD14 surface receptor and, if not, administering to the patient prior to or concurrently with the
endotoxin a cytokine. Also, a composition for treating a cancer, that includes an endotoxin in combination with at least
one cytokine. Administration of the composition can provide more effective treatment of cancers than administration of a
composition containing one or more cytokines alone. The method of the invention, and administration of the composition
according to the invention can induce autocrine and paracrine suppression of growth by leukemic cells, and thus can be
particularly effective for treatment of acute myelogenous leukemia.
14 Claims, No Drawings
[USPTO]
( 15 of 15 ) |
